Wendy Kemmer
Family · Rock Hill, SCNPI 1154706299
Payments from drug & device makers
Across 489 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$557
- AstraZeneca$501
- Astellas Pharma US Inc$475
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$170%
- Food & beverage$8,544100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $1,542 |
| Novo Nordisk | 79 | $1,300 |
| Lilly USA, LLC | 58 | $1,059 |
| Pfizer | 31 | $557 |
| AstraZeneca | 32 | $501 |
| Astellas Pharma US Inc | 21 | $475 |
| Amgen | 19 | $362 |
| Merck | 22 | $354 |
| Bayer | 37 | $333 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $279 |
| Sanofi-aventis U.S. LLC | 11 | $240 |
| Boehringer Ingelheim | 10 | $216 |
| Biohaven Pharmaceuticals, Inc. | 11 | $209 |
| Amarin Pharma, Inc. | 11 | $188 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $169 |
| Novartis | 7 | $148 |
| Esperion Therapeutics, Inc. | 6 | $130 |
| Daiichi Sankyo Inc. | 4 | $101 |
| Inogen, Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $44 |
| GSK | 3 | $43 |
| Exact Sciences | 3 | $43 |
| VBI Vaccine (delaware) Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Mayne Pharma Commercial LLC | 1 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Renalytix AI, Inc. | 1 | $14 |
| Kaleo, Inc. | 1 | $14 |
How this compares
$8,561 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $107,838 |
| MounjaroTirzepatide | 68 | $96,115 |
| RybelsusSemaglutide | 31 | $69,645 |
| VraylarCariprazine Hcl | 38 | $55,932 |
| EliquisApixaban | 39 | $54,172 |
| FarxigaDapagliflozin Propanediol | 32 | $45,056 |
| JardianceEmpagliflozin | 16 | $26,168 |
| JanuviaSitagliptin Phosphate | 22 | $24,725 |
| LinzessLinaclotide | 15 | $21,149 |
| MyrbetriqMirabegron | 19 | $20,704 |
| XareltoRivaroxaban | 14 | $17,056 |
| KerendiaFinerenone | 11 | $14,513 |
| Spiriva RespimatTiotropium Bromide | 11 | $14,243 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $13,331 |
| TrulicityDulaglutide | 13 | $11,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,300 | $177,484106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,059 | $108,07581 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,542 | $78,77175 claims |
| PfizerEliquis | $557 | $54,17239 claims |
| AstraZenecaFarxiga | $501 | $45,05632 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $216 | $40,41027 claims |
| MerckJanuvia, Belsomra | $354 | $32,63540 claims |
| Astellas Pharma US IncMyrbetriq | $475 | $20,70419 claims |
| GSKBreo Ellipta, Anoro Ellipta | $43 | $18,30930 claims |
| BayerKerendia | $333 | $14,51311 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $15 | $5,41711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Rock Hill
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.